Upper Endoscopy Finding | |||||||||
Normal | Gastritis | GU | DU | Reflux esophagitis | Malignancy | Total | p-value | ||
Case numbers (prevalence) | 1174 (56.9%) | 215 (10.4%) | 254 (12.3%) | 194 (9.4%) | 182 (8.8%) | 43 (2.1%) | 2062 (100%) | ||
Age (years) | 47.36 ± 15.43 | 55.42 ± 14.69 | 60.44 ± 15.27 | 51.99 ± 16.24 | 51.87 ± 17.99 | 61.12 ± 14.32 | 0.001a | ||
Gender | Male | 473 (40.3%) | 106 (49.3%) | 142 (55.8%) | 110 (56.7%) | 116 (63.7%) | 30 (69.8%) | 977 (47.4%) | 0.001b |
Female | 701 (59.7%) | 109 (50.7%) | 112 (44.1%) | 84 (43.3%) | 66 (36.3%) | 13 (30.2%) | 1085 (52.6%) | ||
H.P. | Positive | 141 (12.0%) | 75 (51.1%) | 144 (56.7%) | 111 (57.2%) | 8 (4.4%) | 7 (16.2%) | 438 (21.2%) | 0.001b |
Negative | 632 (53.8%) | 110 (34.9%) | 96 (37.8%) | 73 (37.6%) | 111 (61%) | 30 (69.8%) | 1100 (53.3%) | ||
Not done | 401 (34.2%) | 30 (14%) | 14 (5.5%) | 10 (5.2%) | 63 (34.6%) | 6 (14%) | 524 (25.4%) | ||
Combined medication | Nil | 1143 (97.4%) | 197 (91.6%) | 218 (85.8%) | 187 (96.4%) | 177 (97.3%) | 42 (97.7%) | 1964 (25.4%) | |
Aspirin | 19 (1.6%) | 18 (8.4%) | 19 (7.5%) | 3 (1.5%) | 4 (2.2%) | 1 (2.3%) | 64 (3.1%) | 0.001b | |
NSAIDs | 9 (0.8%) | 0 | 15(5.9%) | 4 (2.1%) | 1 (0.5%) | 0 | 29 (1.4%) | 0.001b | |
Coumadin | 3 (0.3%) | 0 | 2 (0.8%) | 0 | 0 | 0 | 5 (2%) | 0.384b | |
Risk factors | Nil | 1105 (94.1%) | 193 (89.8%) | 218 (85.8%) | 163 (84%) | 173 (95.2%) | 17 (39.5%) | 1869 (90.6%) | |
GI bleeds | 23 (2%) | 10 (4.6%) | 21 (8.3%) | 22 (11.3%) | 3 (1.6%) | 9 (20.9%) | 88 (4.3%) | 0.001b | |
BWL | 25 (2.1%) | 6 (2.8%) | 9 (3.5%) | 4 (2.1%) | 3 (1.6%) | 11 (25.6%) | 58 (2.8%) | 0.001b | |
Poor drug response | 20 (1.7%) | 6 (2.8%) | 6 (2.4%) | 5 (2.6%) | 3 (1.6%) | 1 (2.3%) | 41 (2%) | 0.630b | |
Dysphagia | 1 (0.1%) | 0 | 0 | 0 | 0 | 5 (11.6%) | 6 (3%) | 0.001b |